“I believed in the power of PhysioPD when I first saw it twenty-five years ago, I’ve had a passion for it ever since, and now we have enough experience that I know it works.”

—Ron Beaver, PhD, Founder

About Rosa & Co

Rosa was founded in 2002 and remains an employee-owned, science-focused, and client-friendly firm. Today, Rosa is the worldwide commercial leader in PhysioPD-style Research, with comprehensive basic biology and therapeutic experience, industry-leading modeling expertise, and repeat research engagements with a majority of the Top 20 pharmaceutical companies. Rosa's ForecastMD Platforms, which offers a credible methodology for determining expected physician uptake for healthcare products, was started by Bill Brastow, Ph.D., in 2005. Our models have helped shape first-in-class markets including novel therapy combinations for HIV and molecular diagnostic tests for Oncology.

Rosa’s staff bring more than a century of aggregate experience in applying modeling to the inherent challenges faced by drug developers and have authored hundreds of scientific posters, conference presentations, relevant patents, and peer-reviewed publications.

Rosa Leadership in the Community

  • Host Worldwide Webinar Series: Impact of Modeling & Simulation in Drug Development

    Presentations from the pharmaceutical industry, academia, and regulatory agencies


  • International Society of Pharmacometrics

    Chair of the QSP Special Interest Group
    Member of the Variability, Uncertainty, and Error in QSP Models Working Group
    Co-Chair of the Integrating QSP and Machine Learning Working Group
    Member of the Immuno-Oncology Working Group
    Former Member of the QSP Workflows and Methodologies Working Group
    Former Chair of the QSP in Regulatory Interactions Working Group
    Former Secretary of the QSP SIG


  • Strategic Cooperation Agreement with MathWorks®, provider of MATLAB®, and SimBiology®

Recent Highlights

Rosa Co-authors on ISoP Outstanding Research Manuscript Award Article

The International Society of Pharmacometrics has announced the Outstanding Research Manuscript Award for 2023 is “Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clini... Read More

Rosa presentations at ACoP14

Rosa will present a talk and a poster at the Fourteenth American Conference on Pharmacometrics (ACoP14). Dr. Friedrich will present “QSP Modelers – Take Your Data Seriously, Not Literally!” during the Roller Coaster 2 session on Wednesday, 11/8/2... Read More

The Rosa & Co. Executive Team

  • Ron Beaver, PhD

    Ron Beaver, PhD

    Founder, Chairman, and CEO

    Dr. Beaver has over 25 years of experience in the drug–disease modeling industry. Prior to creating Rosa & Co. in 2002, Dr. Beaver collaborated with a global pharmaceutical firm to structure their open-source drug development group. In 1997, Dr. Beaver cofounded Pharsight Consulting Services, a first-generation pharmaceutical modeling company that drove large-scale adoption of leading-edge drug–disease modeling worldwide. Previously, Dr. Beaver was a principal of Pope Street Group (PSG), a...

    Read More

    Dr. Beaver has over 25 years of experience in the drug–disease modeling industry. Prior to creating Rosa & Co. in 2002, Dr. Beaver collaborated with a global pharmaceutical firm to structure their open-source drug development group. In 1997, Dr. Beaver cofounded Pharsight Consulting Services, a first-generation pharmaceutical modeling company that drove large-scale adoption of leading-edge drug–disease modeling worldwide. Previously, Dr. Beaver was a principal of Pope Street Group (PSG), a management consultancy and venture incubator firm. PSG incubated StarMine, a unique quantitative-modeling financial services company (subsequently acquired by Thomson Reuters). Prior to PSG, Dr. Beaver was an associate at Strategic Decisions Group (SDG). In the early 1990s, he closely observed the advancement of predictive biosimulation software which led to the spin-off of Entelos, Inc., the first-generation PhysioPD-style company (acquired by Rosa in 2014). Dr. Beaver holds a PhD in Engineering from Stanford University and a BA from Simpson College, on whose Board of Trustees he served.

    Collapse
  • Christina Friedrich, PhD

    Christina Friedrich, PhD

    Chief Engineer, PhysioPD

    Dr. Friedrich brings over 17 years of leadership expertise in applying mathematical models of biologic/physiologic systems for overcoming development challenges faced by pharmaceutical and consumer product companies. At Rosa (and previously at Entelos, Inc.), she has developed significant experience in the fields of diabetes, blood disorders, CNS disorders, oncology, immuno-oncology, rheumatoid arthritis, respiratory diseases, skin diseases, gastrointestinal disorders, and other immune system ...

    Read More

    Dr. Friedrich brings over 17 years of leadership expertise in applying mathematical models of biologic/physiologic systems for overcoming development challenges faced by pharmaceutical and consumer product companies. At Rosa (and previously at Entelos, Inc.), she has developed significant experience in the fields of diabetes, blood disorders, CNS disorders, oncology, immuno-oncology, rheumatoid arthritis, respiratory diseases, skin diseases, gastrointestinal disorders, and other immune system dysfunctions and inflammatory processes. While at Rosa, Dr. Friedrich developed and published the first peer-reviewed journal article on the qualification of mechanistic mathematical models. Before Rosa, Dr. Friedrich was the Director of Core Product Development at Entelos, Inc., the first-generation leader in PhysioPD-style models. Dr. Friedrich has spearheaded numerous modeling methodologies and contributed to foundational patents, including on the use of virtual patients and populations to explore biological variability and uncertainty, and on the identification of biomarkers. Dr. Friedrich completed her BS at MIT and a PhD in Management Science and Engineering at Stanford University.

    Collapse
  • Mike Reed, PhD

    Mike Reed, PhD

    Chief Scientist, PhysioPD

    Dr. Reed brings 15 years of experience managing large-scale strategic collaborations with client pharmaceutical and consumer product organizations. At Rosa (and previously at Entelos, Inc.), his areas of expertise include metabolic diseases, oncology, central nervous system diseases, and inflammation/immunology. His efforts focus on trial design, target evaluation, competitive differentiation, and novel biomarkers, and has led to several patents and publications. Dr. Reed’s work has been pre...

    Read More

    Dr. Reed brings 15 years of experience managing large-scale strategic collaborations with client pharmaceutical and consumer product organizations. At Rosa (and previously at Entelos, Inc.), his areas of expertise include metabolic diseases, oncology, central nervous system diseases, and inflammation/immunology. His efforts focus on trial design, target evaluation, competitive differentiation, and novel biomarkers, and has led to several patents and publications. Dr. Reed’s work has been presented at dozens of scientific conferences worldwide. Prior to his position at Entelos, Dr. Reed held positions in preclinical pharmacology and drug development at Shaman Pharmaceuticals Inc. and Tularik Inc. (acquired by Amgen Inc.). His contributions include the development of novel animal models for type 2 diabetes. Dr. Reed completed his BS in Biology and MA in Exercise Physiology at The University of Texas at Austin, and a PhD in Exercise Physiology at The Ohio State University. He completed his postdoctoral fellowship at Stanford University, which focused on the mechanistic evaluation of insulin resistance in animal models.

    Collapse
  • Brian Schneider

    Brian Schneider

    Chief Commercial Officer

    For over 25 years, Mr. Schneider has been working with life science organizations at all stages of the drug development pipeline. By asking questions and bringing insights, he has developed trusting relationships with clients attempting to make the best decisions with the most relevant data. Prior to joining Rosa in 2023, Mr. Schneider has sold reagents, instrumentation and services in a variety of markets including microscopy, image analysis, tissue diagnostics, immuno-assays, DNA synthesis a...

    Read More

    For over 25 years, Mr. Schneider has been working with life science organizations at all stages of the drug development pipeline. By asking questions and bringing insights, he has developed trusting relationships with clients attempting to make the best decisions with the most relevant data. Prior to joining Rosa in 2023, Mr. Schneider has sold reagents, instrumentation and services in a variety of markets including microscopy, image analysis, tissue diagnostics, immuno-assays, DNA synthesis and genome engineering. Mr. Schneider holds an S.M. in Biology from MIT and a B.S. in Biochemistry from the University of Rochester in NY.

    Collapse